
Yumiko Akamine

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3040098/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Drug-Drug Interactions of P-gp Substrates Unrelated to CYP Metabolism. Current Drug Metabolism, 2019, 20, 124-129.	1.2	33
2	The change of pharmacokinetics of fexofenadine enantiomers through the single and simultaneous grapefruit juice ingestion. Drug Metabolism and Pharmacokinetics, 2015, 30, 352-357.	2.2	31
3	Quantification of the steady-state plasma concentrations of clozapine and N-desmethylclozapine in Japanese patients with schizophrenia using a novel HPLC method and the effects of CYPs and ABC transporters polymorphisms. Annals of Clinical Biochemistry, 2017, 54, 677-685.	1.6	17
4	An update on the clinical pharmacokinetics of fexofenadine enantiomers. Expert Opinion on Drug Metabolism and Toxicology, 2018, 14, 429-434.	3.3	14
5	Multiple inductive effects of carbamazepine on combined therapy with paliperidone and amlodipine. Journal of Clinical Pharmacy and Therapeutics, 2015, 40, 480-482.	1.5	10
6	Prediction of Tacrolimus Exposure by CYP3A5 Genotype and Exposure of Co-Administered Everolimus in Japanese Renal Transplant Recipients. International Journal of Molecular Sciences, 2018, 19, 882.	4.1	9
7	ABCC2 C421A polymorphisms affect exposure of the epidermal growth factor receptor inhibitor gefitinib. Investigational New Drugs, 2020, 38, 1687-1695.	2.6	8
8	A comparison of the effects of <i> <scp>CYP</scp> 3A5 </i> polymorphism on tacrolimus blood concentrations measured by 4 immunoassay methods in renal transplant patients. Journal of Clinical Pharmacy and Therapeutics, 2018, 43, 181-188.	1.5	7
9	Quantification of the Plasma Concentrations of Perampanel Using High-Performance Liquid Chromatography and Effects of the CYP3A4*1G Polymorphism in Japanese Patients. Journal of Chromatographic Science, 2020, 58, 915-921.	1.4	7
10	Comparison of electrochemiluminescence immunoassay and latex agglutination turbidimetric immunoassay for evaluation of everolimus blood concentrations in renal transplant patients. Journal of Clinical Pharmacy and Therapeutics, 2018, 43, 675-681.	1.5	6
11	Influence of ABCB1 polymorphisms on the pharmacokinetics and toxicity of lenalidomide in patients with multiple myeloma. Medical Oncology, 2019, 36, 55.	2.5	6
12	Influence of everolimus on the pharmacokinetics of tacrolimus in Japanese renal transplant patients. International Journal of Urology, 2016, 23, 484-490.	1.0	5
13	Changes in PCSK9 and LDL cholesterol concentrations by everolimus treatment and their effects on polymorphisms in PCSK9 and mTORC1. Pharmacological Reports, 2020, 72, 622-630.	3.3	5
14	Tacrolimus concentrations after renal transplantation in a motherâ€neonate dyad: Maternal, neonatal and breast milk measurements. Journal of Clinical Pharmacy and Therapeutics, 2021, 46, 1800-1803.	1.5	4
15	Drug interactions between warfarin and lenvatinib in a patient with the <i>CYP2C9</i> * <i>1/*3</i> and <i>VKORC1</i> â€1639G/A genotype. Journal of Clinical Pharmacy and Therapeutics, 2019, 44, 977-980.	1.5	3
16	Effects of proprotein convertase subtilisin/kexin type 9 and nilotinib plasma concentrations on nilotinibâ€induced hypercholesterolaemia in patients with chronic myeloid leukaemia. Journal of Clinical Pharmacy and Therapeutics, 2021, 46, 382-387.	1.5	3
17	Relationship between achievement of major molecular response or deep molecular response and nilotinib plasma concentration in patients with chronic myeloid leukemia receiving first-line nilotinib therapy. Cancer Chemotherapy and Pharmacology, 2022, 89, 609-616.	2.3	2
18	Effects on monotherapy and reduction of antipsychotic drugs by clozapine therapy in Japanese patients with treatmentâ€resistant schizophrenia. Journal of Clinical Pharmacy and Therapeutics, 2021, 46, 1312-1318.	1.5	1

#	Article	IF	CITATIONS
19	Associations Between Plasma Concentrations of Lenvatinib and Angiopoietin and Clinical Responses to Lenvatinib Therapy in Japanese Patients With Thyroid Cancer. Cancer Diagnosis & Prognosis, 2022, 2, 336-344.	0.7	0